MCM
AXSM icon

Moore Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Moore Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,800
Closed -$685K – 445
2023
Q3 		$685K Sell
9,800
-5,200
-35% -$389K 0.01% 321
2023
Q2 		$1.08M Buy
+15,000
New +$1.11M 0.02% 296

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Moore Capital Management's AXSM Position: Q4 2023 in Review

Moore Capital Management sold out of Axsome Therapeutics (AXSM) in Q4 2023, closing a stake of 9,800 shares — an estimated $685K sold.

Moore Capital Management first reported a position in AXSM in Q2 2023 and held it in 2 quarters. The position peaked at $1.08M in Q2 2023. 244 funds tracked by Wall St. Rank hold AXSM as of Q4 2023.

  • Moore Capital Management reported no remaining Axsome Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Moore Capital Management sold 9,800 Axsome Therapeutics shares in Q4 2023, an estimated $685K.
  • Moore Capital Management first reported a position in Axsome Therapeutics in Q2 2023 and held it in 2 quarters.
  • Moore Capital Management's Axsome Therapeutics position peaked at $1.08M in Q2 2023.
  • 244 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.